** Shares of drug developer Vigil Neuroscience VIGL.O rise 10% to $2.25
** VIGL says its experimental Alzheimer's drug, VG-3927, reduced key biomarker sTREM2 by up to 50% in cerebral spinal fluid in early-stage trial
** Reduction in sTREM2 levels is expected to help slow progression of Alzheimer's disease, as higher levels suggest brain inflammation
** Co says VG-3927 was well-tolerated and has favorable pharmacokinetic and pharmacodynamic profile in the trial
** VIGL plans to advance into mid-stage trial in Q3 2025
** 8 of 9 brokerages rate stock "buy" or higher and 1 "sell"; their median PT is $16.50 - data compiled by LSEG
** VIGL fell ~51% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.